- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market
We spoke to Charles Bennett, MD, PhD, a clinical pharmacy specialist, about his recent oncology biosimilars study and how pay-for-delay schemes have somewhat stalled the biosimilar market.
Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, served as lead author on a recent paper about the progress of oncology biosimilars. We spoke to him about the some of the findings of his study and how pay-for-delay schemes have somewhat stalled the biosimilar market.
To read more about Bennett's study, click here.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.
